These findings suggest that IL6R and MYC act as key modulators contributing to cancer malignancy and enabling Imatinib resistance in CML, highlighting their potential as therapeutic targets. The gene discussed is MYC; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.